CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
We tested the efficacy and safety of glutamine (0.6 gm/kg/day) and creatine (5 gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, double-blind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.
Escolar
Diana M
DM
Children's National Medical Center, George Washington University, Washington, DC, USA. descolar@cnmcresearch.org
Buyse
Gunnar
G
Henricson
Erik
E
Leshner
Robert
R
Florence
Julaine
J
Mayhew
Jill
J
Tesi-Rocha
Carolina
C
Gorni
Ksenija
K
Pasquali
Livia
L
Patel
Kantilal M
KM
McCarter
Robert
R
Huang
Jennifer
J
Mayhew
Thomas
T
Bertorini
Tulio
T
Carlo
Jose
J
Connolly
Anne M
AM
Clemens
Paula R
PR
Goemans
Nathalie
N
Iannaccone
Susan T
ST
Igarashi
Masanori
M
Nevo
Yoram
Y
Pestronk
Alan
A
Subramony
S H
SH
Vedanarayanan
V V
VV
Wessel
Henry
H
D002648:Child; D002675:Child, Preschool; D003401:Creatine / Q000627:therapeutic use*; D005973:Glutamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects*; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy*; D012129:Respiratory Function Tests
D005973:Glutamine; D003401:Creatine